Payment overview · 2025
General Payments
$526.44
19 reported records · 9 companies
Healthcare provider profile · identity verified
Robert M Mahaffey, MD
Allopathic & Osteopathic Physicians|Family Medicine · TULSA, OK · NPI 1013971191
Verified facts
What the public records show
CMS Open Payments records show Robert M Mahaffey, MD received $526.44 in general payments during 2025 across 19 reported records.
Pulmonx Corporation accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $147.06 | 27.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $76.22 | 14.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $75.74 | 14.4% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $64.19 | 12.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.21 | 10.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.93 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.61 | 5.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.83 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.65 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $526.44 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $147.06 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $147.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $147.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $147.06 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $76.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $75.74 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $64.19 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.21 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 15 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 562 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 504 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 98 |
| Omeprazole | Omeprazole | 318 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 314 | 66 |
| Losartan Potassium | Losartan Potassium | 272 | 82 |
| Lisinopril | Lisinopril | 218 | 66 |
| Simvastatin | Simvastatin | 212 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 62 |
| Tramadol Hcl | Tramadol Hcl | 192 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 190 | 52 |
| Furosemide | Furosemide | 183 | 60 |
| Alprazolam | Alprazolam | 181 | 27 |
| Trazodone Hcl | Trazodone Hcl | 159 | 42 |
| Potassium Chloride | Potassium Chloride | 151 | 46 |
| Alendronate Sodium | Alendronate Sodium | 137 | 36 |
| Eliquis | Apixaban | 137 | 34 |
| Gabapentin | Gabapentin | 133 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 45 |
| Glimepiride | Glimepiride | 126 | 38 |
| Metformin Hcl Er | Metformin Hcl | 126 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 43 |
| Azithromycin | Azithromycin | 115 | 93 |
| Carvedilol | Carvedilol | 115 | 28 |
| Benazepril Hcl | Benazepril Hcl | 108 | 29 |
| Metformin Hcl | Metformin Hcl | 105 | 37 |
| Estradiol | Estradiol | 103 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 27 |
| Meloxicam | Meloxicam | 101 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 34 |
| Ozempic | Semaglutide | 100 | 23 |
| Montelukast Sodium | Montelukast Sodium | 99 | 31 |
| Spironolactone | Spironolactone | 99 | 31 |
| Allopurinol | Allopurinol | 94 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 94 | 73 |
| Bupropion Hcl Sr | Bupropion Hcl | 93 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 16 |
| Donepezil Hcl | Donepezil Hcl | 82 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 20 |
| Jardiance | Empagliflozin | 82 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 28 |
| Prednisone | Prednisone | 77 | 51 |
| Finasteride | Finasteride | 76 | 25 |
| Memantine Hcl | Memantine Hcl | 75 | 22 |
| Propranolol Hcl | Propranolol Hcl | 74 | 24 |
| Famotidine | Famotidine | 72 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | suppressed |
| Ibuprofen | Ibuprofen | 68 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 11 |
| Pregabalin | Pregabalin | 64 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 36 |
| Azelastine Hcl | Azelastine Hcl | 62 | 32 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 13 |
| Ketoconazole | Ketoconazole | 59 | 32 |
| Ramipril | Ramipril | 56 | 14 |
| Valsartan | Valsartan | 54 | 18 |
| Januvia | Sitagliptin Phosphate | 53 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 12 |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Amoxicillin | Amoxicillin | 51 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 12 |
| Celecoxib | Celecoxib | 49 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 13 |
| Topiramate | Topiramate | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Aripiprazole | Aripiprazole | 43 | 15 |
| Mirtazapine | Mirtazapine | 43 | 17 |
| Linzess | Linaclotide | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 42 | 13 |
| Fluconazole | Fluconazole | 40 | 18 |
| Atenolol | Atenolol | 39 | 12 |
| Glipizide Er | Glipizide | 39 | 13 |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 26 |
| Venlafaxine Hcl | Venlafaxine Hcl | 34 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | 13 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 19 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 11 |
| Testosterone | Testosterone | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Diazepam | Diazepam | 18 | 11 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Baclofen | Baclofen | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 12 |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Pregabalin Er | Pregabalin | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $526.44 · 19 records | Pulmonx Corporation | ABRYSVO, CAPLYTA, CHARTIS CATHETER, COMIRNATY, Cologuard Collection Kit, JARDIANCE, MOUNJARO, Omnipod, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, Veozah, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error